Abstract
Microarrays and biochips are small devices capable of detecting and measuring
large numbers of biomarkers simultaneously. Although microarrays have been in
research use for over a decade it is only recently that they have moved
towards meeting the requirements of the clinical and regulatory communities
with the first DNA microarray test being approved by the US FDA in 2007.
Further development of microarrays heralds the introduction of faster
diagnosis times and will further enable personalized medicine. This report
covers future developments in key segments of the microarray market including
DNA, protein, tissue and cell microarrays and lab-on-a-chip technologies,
providing market forecasts to 2013. In addition the report gives insights into
the developmental programs of 45 leading players in this market.
| 
View Cart
